BeOne Medicines — Third Quarter 2026 Earnings Summary

BeOne Medicines reported third-quarter 2026 total global revenues of $1.9 billion, marking a 34% increase from the prior year, driven primarily by $1.4 billion in sales of its BTK inhibitor BRUKINSA. The company achieved diluted GAAP earnings per ADS of $3.28 and raised its full-year 2026 revenue guidance to a range of $6.9 billion to $7.0 billion. Key business updates include FDA Priority Review designation for BRUKINSA in first-line mantle cell lymphoma, regulatory approvals for TEVIMBRA in nasopharyngeal cancer and HER2+ gastroesophageal adenocarcinoma, and the initiation of several new Phase 3 clinical studies across hematology and solid tumors.